Statistics

Total Visits

Views
Consistent benefit survival with cabazitaxel (CBZ) in metastatic castration resistant prostate cancer (mCRPC) in Spain: Updated results86

Select a period of time:

Number of views in the range

Views
Consistent benefit survival with cabazitaxel (CBZ) in metastatic castration resistant prostate cancer (mCRPC) in Spain: Updated results17

Views

Views
September 20253
October 20257
November 20252
December 20252
January 20261
February 20261
March 20261
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States7
Brazil3
United Kingdom2
Venezuela2
Argentina2
Egypt1
 

Top cities views

Views
Dallas1
Fortaleza1
Juazeiro do Norte1
Kintore1
La Guaira1
Los Polvorines1
Maracaibo1
Mendoza1
Minya1
San Antonio1